Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 4/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | POLA1 | P09884 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10788490 | 0.93 | KDM4E (0.49) | KDM4ETYMPTAS1R3TAS1R1P2RY1 | |
| SCHEMBL23157264 | 0.91 | KDM4E (0.48) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| Pyridine SCHEMBL10491050 | 0.91 | KDM4E (0.47) | KDM4ETYMPTAS1R3TAS1R1P2RY1 | |
| SCHEMBL3820892 | 0.87 | KDM4E (0.56) | KDM4ETYMPTAS1R3TAS1R1P2RY1 | |
| SCHEMBL11016436 | 0.86 | KDM4E (0.45) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL30622441 | 0.85 | KDM4E (0.49) | KDM4ETYMPTAS1R3TAS1R1P2RY1 | |
| SCHEMBL31724038 | 0.85 | KDM4E (0.48) | KDM4ETYMPTAS1R3TAS1R1P2RY1 | |
| SCHEMBL21828783 | 0.85 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1P2RY1 | |
| SCHEMBL14063336 | 0.85 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1P2RY1 | |
| SCHEMBL17911710 | 0.85 | KDM4E (0.53) | KDM4ETYMPTAS1R3TAS1R1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | KDM4E 4623/4885TYMP 2728/4885TAS1R3 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.